Since our last article discussing Kintara Therapeutics (NASDAQ: KTRA) underappreciated value proposition to investors, CEO Saiid Zarrabian has solidified the company’s position for growth in 2021 and … [Read more...] about Kintara Therapeutcis (NASDAQ: KTRA)….
You must be logged in to post a comment.